{"id":"W4324136309","doi":"10.1200/jco.2023.41.6_suppl.19","title":"Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Docetaxel; Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Placebo; Interim analysis; Internal medicine; Pembrolizumab; Randomization; Abiraterone acetate; Oncology; Prednisone; Randomized controlled trial; Androgen deprivation therapy; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002761321,0.002318383,0.002450472,0.0005252613,0.0006477041,0.001361189,0.00120016,0.00207265,0.01032675],"category_scores_gemma":[0.001700246,0.00115085,0.001756639,0.0006012881,0.00122691,0.001421469,0.0005309365,0.003911654,0.002086538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000993185,"about_ca_system_score_gemma":0.002015448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001212728,"about_ca_topic_score_gemma":0.003594424,"domain_scores_codex":[0.9992943,0.0003490235,0.00003850209,0.000138584,0.0000665719,0.0001130161],"domain_scores_gemma":[0.999204,0.0001481673,0.0002279672,0.0000611729,0.00005478925,0.0003038837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9614963,0.01840444,0.0005221746,0.0009336104,0.0006403787,0.0000396982,0.00006597322,0.0003382051,0.004027132,0.0001015668,0.001500423,0.01193007],"study_design_scores_gemma":[0.9310546,0.06637876,0.001049345,0.00002698996,0.0001987432,0.00003068319,0.0000118675,0.0001715569,0.0002545074,0.00008133566,0.0007300612,0.00001153105],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9529531,0.006715209,0.001446418,0.001198623,0.0009465831,0.02745671,0.004499622,0.0003281139,0.004455552],"genre_scores_gemma":[0.9596837,0.004362133,0.003455731,0.002833158,0.0006803242,0.01891072,0.002647604,0.00006657939,0.007360072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01032675,"threshold_uncertainty_score":0.03454638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.21805030031091,"score_gpt":0.538259259351251,"score_spread":0.320208959040341,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}